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Abstract: Nasal high ﬂow (NHF) is a promising novel oxygen delivery device, whose
mechanisms of action offer some beneﬁcial effects over conventional oxygen systems. It is
considered to have a number of physiological effects: it improves oxygenation, dynamic lung
compliance, homogeneity and end expiratory lung volume; it decreases anatomical dead
space and generates a positive airway pressure that can reduce respiratory rate, the work of
breathing, and enhance patient comfort. NHF has been used as a prophylactic tool or as a
treatment device mostly in patients with acute hypoxemic respiratory failure such as pre-
oxygenation before intubation, immunocompromised patients and acute heart failure.
Moreover, there is some evidence that NHF could be used during procedural sedation.
Finally, NHF was deemed to be effective in chronic obstructive pulmonary disease patients
with its positive end expiratory pressure effects and dead-space washout. However, careful
monitoring is crucial to maximize NHF settings aimed at maximizing patient comfort while
limiting the risk of delayed intubation. The present review presents the most updated
evidence for NHF use in the adult acute care setting with the goal of providing clinicians
with useful insights on the physiologic effects, main clinical indications, and safety issues of
NHF treatment.
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Introduction
Nasal high ﬂow (NHF) is a noninvasive respiratory support designed to deliver 30–
60 L/minute of a heated, humidiﬁed mixture of air and oxygen through speciﬁcally
designed nasal prongs. NHF allows modiﬁcation of two main settings—the percen-
tage of oxygen delivered and the rate of gas ﬂow. NHF can deliver a mix of air and
oxygen with an inspired oxygen fraction (FiO2) ranging between 0.21 and 1.0 and
the ﬂow rate ranges from 30 to 60 L/minute. Thus, NHF is not necessarily a very
high ﬂow of pure oxygen as often wrongly referred to in previous publications.
Recently, NHF has gained increasing popularity in treating both type I (hypoxemic)
and type II (hypoxemic/hypercapnic) acute respiratory failure (ARF) globally.
However, the physiologic effects of NHF on the respiratory system function, and
its inﬂuence on clinical outcomes are still open research ﬁelds, with new studies
being published every week or so. The present review presents the most updated
evidence for NHF use in the adult acute care setting (ie, from the emergency
department to the intensive care unit, ICU) with the goal of providing clinicians
with useful insights on the physiologic effects, main clinical indications and safety
issues of NHF treatment.
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Physiological effects
The main physiological effects of NHF are maintenance of
a known stable alveolar FiO2, optimal humidiﬁcation of
the airway mucosa, reduction of the dead space, generation
of a positive end-expiratory pressure (PEEP), ultimately
yielding a reduction in the respiratory drive and in the
work of breathing (see Table 1).
Stable alveolar FiO2
Low-ﬂow nasal cannulas are connected to the hospital gas
delivery system via ﬂowmeters, most of which allow
delivery of gas ﬂows up to 15 L/minute. Traditional
nasal cannula ﬂow rate has been limited, not only due to
the internal diameter of the cannula, but also by the risks
associated with the lack of heating and humidiﬁcation of
the inspired gas. In dyspneic ARF patients, when the
inspiratory ﬂow rate exceeds the ﬂow delivered, additional
ﬂow is entrained from the surrounding room air.
Consequently, traditional low ﬂow nasal cannula cannot
deliver constant alveolar FiO2, even at the highest ﬂow
rates.1,2 NHF very high ﬂow rates can match the inspira-
tory demand of dyspneic patients and overcome the need
of additional room air-mixing, ﬁnally providing stable
delivered alveolar FiO2.
3 In the abovementioned range
from 30 to 60 L/minute, bench studies showed that the
FiO2 measured in distal airways is very close to the set
FiO2.
4 Recently, Parke et al5 performed a study on healthy
volunteers with NHF delivered with ﬂow exceeding 60 L/
minute. If heating and humidiﬁcation can be granted as
such high ﬂow rates, this study suggests that alveolar FiO2
during NHF could be high and stable even in the most
severe patients. NHF, in the presence of stable oxygen
consumption and CO2 production, likely improves the
correspondence between set and alveolar FiO2, but the
extent of this beneﬁt is difﬁcult to predict in clinical
practice.
Humidiﬁcation
Conventional oxygen devices delivering dry and cold
gases usually causes discomfort, nasal and oral dryness,
Table 1 Key physiological beneﬁts of NHF, divided between those already described in recent literature and still to be assessed in
prospective studies
Key physiological beneﬁts of NHF
Already described
Improvement of oxygenation Mauri et al , Am J Respir Crit Care Med 201720
Möller et al, J Appl Phyiol 201711
Reduction of respiratory rate Mauri et al, Am J Respir Crit Care Med 201720
Corley et al, Br J Anaesth 201115
Increased CO2 clearance Möller et al, J Appl Physiol 2017
11
Mauri et al, Am J Respir Crit Care Med201720
PEEP effect (increased pharyngeal pressure and lung volume) Parke et al, Respir Care 201128
Corley et al, Br J Anaesth 201115
Reduction of work of breathing Sztrymf et al, Intensive Care Med 201122
Itagaki et al, Respir Care 201423
Mauri et al, Intensive Care Med 201725
Limit the risk of P-SILI: decrease lung stress, strain, heterogeneity Mauri et al, Am J Respir Crit Care Med 201720
Optimal comfort Roca et al, Respir Care 201026
Mauri et al, Critical Care 201876
Lenglet et al, Respir Care 201264
Still hypothetical
Improved matching between set and alveolar FiO2
Optimization of mucociliary cells function
Reduced CO2 production from mucosal epithelium and inspiratory muscles
Decreased respiratory drive
Increased expiratory transpulmonary pressure
Decreased inspiratory transalveolar pressure
Abbreviations: NHF, nasal high ﬂow; CO2, carbon dioxide; PEEP, positive end-expiratory pressure; P-SILI, patients’ self-inﬂicted lung injury; FiO2, fraction of inspired
oxygen.
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eye irritation, nasal and eye trauma.6,7 Inspired gases,
when unwarmed and dry, may yield a variety of untoward
effects on ARF patients on respiratory support. As the
airway dries and cool down, mucociliary function gets
impaired and it is more difﬁcult to clear the airway of
secretions. NHF, instead, undergoes 100% humidiﬁcation
and is heated up to approximately normal body tempera-
ture. Effective humidiﬁcation and heating will cause less
mucociliary dessication,8 thus granting more efﬁcient
mucociliary clearance, facilitating clearance of secretions,
and decreasing the risk of occlusion atelectasis, ﬁnally
resulting in improved ventilation/perfusion matching and
oxygenation. Better humidiﬁcation and heating could
mean improved comfort, too. Saslow et al described
greater compliance in infants supported with 5 L/minute
of NHF with conditioned gas compared to 6 cm H2O of
conventional continuous positive airway pressure
(CPAP).9
Dead space washout
The continuous high ﬂow rate provided by NHF washes the
residual volume of carbon dioxide (CO2) lying in the upper
airways from previous breath and replaces it with CO2-free
oxygen-enriched gas. In a lung-injured-animal model,
PaCO2 decreased as NHF ﬂow increased, as higher rates of
gas ﬂow more effectively washed out CO2. These results
suggest effective carbon dioxide washout with NHF.10
Moreover, in healthy volunteers, Möller et al showed rapid
and effective wash out of radiological tracer from the upper
airways by NHF.11 As patients using the NHF may open or
close their mouth at will, this might inﬂuence alveolar FiO2
and CO2 washout. Wettstein et al compared FiO2 in healthy
volunteers breathing with mouth open and closed12 and,
counterintuitively, FiO2 was higher during mouth-open
breathing. This may have been due to the reservoir function
of the nose, the pharynx, and, potentially, the oral cavity after
being washed out from exhaled CO2. By allowing NHF to
continually suffuse the nasal cavity during exhalation,
breathing with the mouth open may enable more efﬁcient
CO2 washout and provide a larger anatomic reservoir. Thus,
these mechanisms suggest that CO2 washout may contribute
to the observed increase in alveolar FiO2.
PEEP effect and lung volumes
Research measuring pressure in the lower pharynx
showed positive linear correlation between PEEP and
the amount of ﬂow delivered by NHF. Moreover,
Groves et al13 described that PEEP is determined by
ﬂow also in the presence of mouth open. In healthy
volunteers, mean airway pressure associated with NHF
at 0, 10 20, 40 and 60 L/minute with the mouth closed
was 0.8, 1.7, 2.9, 5.5 and 7.7 cm H2O, respectively.
Similar positive pressure effect was reported in the
studies performed by Ritchie et al14 and Corley et al15
in hypoxemic patients. Moreover, Parke et al5 per-
formed a study on healthy volunteers to describe if the
correlation remains linear at ﬂows exceeding 50 L/min-
ute. On average, for every 10 L/minute increase in gas
ﬂow, the generated mean airway pressure increased by
1.16 cm H2O. NHF support was associated with an
increase in end-expiratory lung volume (EELV), which
indicates positive alveolar pressure at end-expiration, a
decrease in respiratory rate (RR), and a more uniform
distribution of alveolar ventilation between lung regions.
The increase of EELV related to the use of NHF seems
independent from changes in body position. Riera et
al16 described an increase in EELV with the use of
NHF in both supine and prone positions. Plotnikow et
al17 assessed EELV changes induced by NHF use at
different ﬂows in healthy subjects in the semi-seated
position. Global and regional EELV measured by elec-
trical impedance tomography also increased with
increasing ﬂows. A strong correlation between airway
pressure and increase of EELV was described by Corley
et al15 in adult patients treated with NHF after cardi-
othoracic surgery. Compared with conventional oxygen
therapy, NHF increased EELV, reduced the respiratory
rate and increased the tidal volume (Vt). Finally, in the
research performed by Mündel et al18 who used an
elastic sensor belt for polysomnography to measure Vt
in healthy volunteers, NHF led to a marked increase in
Vt. Okuda et al19 also demonstrated Vt increase at
different ﬂows and Vt seemed to correlate with NHF
ﬂow rate. Corley et al15 reported similar ﬁndings, too.
However, Mauri et al20 described stable Vt in hypoxe-
mic patients during NHF vs low-ﬂow oxygen mask and
Bräunlich et al21 reported decreased Vt in healthy
volunteers during NHF. It might be possible that
patients with acute lung injury supported by NHF do
not reduce the tidal volume because of disease-related
high respiratory drive. Thus, conclusions on the effects
of NHF on Vt are still lacking, and differences in age,
sex, clinical condition and the methods used to measure
Vt may explain heterogeneous ﬁndings.
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Reduction of respiratory drive
Nearly all studies conducted both in healthy volunteers
and in ARF patients reported decreased respiratory rate
and improved dyspnea during NHF compared to standard
low-ﬂow oxygen. These ﬁndings suggest that the central
respiratory drive could be reduced by NHF, likely through
the interaction between all the abovementioned mechan-
isms: increased alveolar FiO2 could lead to improved
oxygenation and decreased hypoxic drive, effective humi-
diﬁcation could reduce discomfort, dead space washout
reduces the minute ventilation needed to maintain stable
arterial CO2 level and the hypercapnic drive, and ﬁnally
the PEEP effect could contribute to improved oxygenation
and to improved respiratory system mechanics with easier
ability to inspire the desired Vt.20
Reduction of work of breathing
NHF could also decrease the work of breathing, depending
on the clinical condition of the patient. Sztrymf et al22
showed an improvement in subjective measures of inspira-
tory load by NHF in the patients diagnosed as having poor
thoraco-abdominal coordination under standard low-ﬂow
oxygen. The same results were obtained by Itagaki et al23
in patients with mild to moderate respiratory failure treated
with the NHF after thoracotomy. Previous studies also
described the reduction of inspiratory effort and work of
breathing by NHF, as quantiﬁed by esophageal pressure
inspiratory swings in pediatric populations.9,24 Mauri et
al25 performed a prospective randomized crossover study
in adults nonintubated patients with hypoxemic ARF.
Measures of inspiratory effort and metabolic work of
breathing assessed by esophageal pressure signiﬁcantly
decreased during NHF therapy (Figure 1). The authors
also suggested that NHF could improve other key physio-
logic parameters including dynamic lung compliance,
transpulmonary pressure, and homogeneity. Similar effects
on reduction of effort and work of breathing were reported
in stable patients with COPD (see the section below).
Clinical indications in hypoxemic
patients
Acute hypoxemic respiratory failure
NHF is becoming the ﬁrst-line treatment for acute hypoxe-
mic respiratory failure (AHRF) patients when standard
oxygenation via facial mask or nasal cannula yields poor
oxygenation and immediate intubation is not required.
Facial mask, time (seconds)
A B
C D
∆Pes ∆Pes
Es
op
ha
ge
al
 p
re
ss
ur
e 
(c
m
H
2O
)
Es
op
ha
ge
al
 p
re
ss
ur
e 
(c
m
H
2O
)
R
es
pe
rit
or
y 
ra
te
 (b
re
at
h 
m
in
-1
)
NHF, time (seconds)
Facial mask NHF 30 NHF 45 NHF 60Facial mask NHF 30 NHF 45 NHF 60
∆ 
Pe
s 
(c
m
H
2O
)
Figure 1 Tracing of esophageal pressure swings (ΔPes) during (A) low ﬂow oxygenation compared to (B) nasal high ﬂow support, showing reduced inspiratory effort.
Indeed, respiratory rate (C) and inspiratory effort (D) decreased with increasing NHF ﬂow rate.
Abbreviations: NHF, nasal high ﬂow; ΔPes, esophageal pressure swings.
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The beneﬁts of NHF therapy compared to standard
oxygen has been widely described since the ﬁrst study of
Roca et al26 in adult patients in 2010. It reported an
increase in both SaO2 and PaO2 and comfort with a
decrease of respiratory rate and dyspnea. These results
were further conﬁrmed by Sztrymf et al27 who also
reported important hints on early recognition of NHF fail-
ure and the need for consideration for intubation.22
Compared to conventional oxygen therapy, NHF could
be more effective in mild to moderate AHRF also in
reducing the need for escalation to noninvasive ventilation
(NIV).28
But it was not until the ﬁrst large randomized clinical
trial by Frat et al,29 the FLORALI trial, that NHF admi-
nistered at 50 L/minute was compared both to NIV (for at
least 8 hours per day) and standard oxygen (face mask at
10 L/minute or more) in terms of hard clinical outcomes.
In patients with a PaO2/FiO2 ratio ≤300 with AHRF (84%
with pneumonia as primary diagnosis), NHF was not
superior to the other two treatments in lowering intuba-
tion rate, the primary outcome. However, a post-hoc
analysis found that NHF signiﬁcantly reduced intubation
in the subgroup with PaO2/FiO2 ratio ≤200. Ventilator-
free days and 90 day mortality, described as secondary
outcomes, were reduced by NHF in the whole popula-
tion, too.
These results were challenged by a second large
randomized clinical trial, the HOT-ER trial,30 comparing
the administration of NHF starting from 30 L/minute to
face mask oxygenation up to 15 L/minute in the emer-
gency department. NHF resulted in lower rates of intu-
bation after 24 hours (although with a marginal
statistical signiﬁcant, P=0.053). No differences in mor-
tality at 90 days was found. However, HOT-ER popula-
tion was different and very heterogeneous, with lower
percentage of community acquired pneumonia patients
and without the exclusion of COPDand asthma
exacerbations.
Two recent systematic reviews and meta-analyses
were published to better clarify these aspects. The
ﬁrst included over 3,000 AHRF patients and described
that NHF reduced the need for endotracheal intubation
compared to conventional oxygen and NIV (OR: 0.60,
95%CI:0.41–0.86).31 The second32 included 1,084
patients and reported that, compared to conventional
oxygen and NIV, NHF could reduce both the rate of
endotracheal intubation (OR: 0.62 and OR: 0.48,
respectively) and ICU mortality (OR: 0.47 and OR:
0.36, respectively) when used before mechanical
ventilation.
Although still relatively few, these data seem to indi-
cate that NHF should be considered as ﬁrst-line therapy
for patients with AHRF.
Acute hypoxemic respiratory failure in
immunosuppressed patients
Intubation in immunosuppressed patients with AHRF is
associated with extremely elevated mortality, hence a
respiratory management aiming to avoid intubation should
be promoted.
A post-hoc analysis of the FLORALI trial showed that
NIV increased intubation and mortality compared to NHF
or conventional oxygen in immunosuppressed patients.33
The same results were obtained in a prospective observa-
tional study with NHF compared to NIV, both used as ﬁrst-
line therapy.34 Moreover, NHF compared to NIV and face
mask oxygen, respectively, was associated with lower
mortality in speciﬁc cohorts, such as cancer patients35
and lung transplantrecipients.36
More recently, the HIGH randomized clinical trial37
compared continuous NHF therapy to standard oxygen
therapy in 778 immunocompromised patients with
AHRF. Azoulay et al found no statistically signiﬁcant
differences in 28-day mortality (35.6% vs 36.1%,
P=0.94), intubation rate (38.7% vs 43.8%, P=0.17) and
ICU mortality (31.7% vs 31.4%, P=0.77), with no comfort
and dyspnea score improvement by NHF therapy.
However, the population was very heterogeneous and the
authors concluded that attention to oxygenation strategies
may not be the main focus in such a diverse population.
Preoxygenation for intubation
The main goal of preoxygenation is to extend the period of
safe apnea, thus avoiding a desaturation below 88% during
intubation manuever. This is usually achieved by obtaining
an arterial oxyhemoglobin saturation as close as possible
to 100% and by the denitrogenation of the lungs (ie, the
wash out of nitrogen contained in room air, increasing
alveolar oxygen reservoir). These aspects might be both
promoted by the dead-space washout and PEEP effect of
the NHF therapy. Moreover, compared to other facial
devices, NHF support can be kept during the maneuver.
In the operating theatre, preoxygenation with NHF was
applied to a cohort of 50 patients undergoing scheduled
awake ﬁberoptic intubation for expected difﬁcult airways
Dovepress Mauri et al
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management. The therapy was generally well tolerated,
with no desaturation below 90% despite the length of
procedures (up to 17 minutes).38 In the same clinical
setting, NHF at 70 L/minute for 10 minutes during induc-
tion was tested to deliver apneic oxygenation: Patel et al39
associated NHF oxygenation to jaw thrust to increase
apnea time during induction of general anesthesia and
difﬁcult airways management with no desaturation and
stable CO2 level. These results were further conﬁrmed by
a randomized clinical trial, highlighting NHF potential
compared to face mask during preoxygenation for rapid
sequence induction of anesthesia.40
In critically ill patients, given the possible combination
of reduced pulmonary functional residual capacity and a
compromised cardiovascular reserve, achieving an optimal
oxygenation status during intubation is mandatory. Despite
preliminary promising evidences,41 preoxygenation by
NHF did not prevent occurrence of severe hypoxemia
compared to standard clinical practice (ie administering
oxygen through a non-rebreathing bag reservoir
facemask)42 irrespective of baseline patients’ oxygenation
status.43 It could be inferred that in patients with AHRF as
primary reason for intubation, the PEEP and the apneic
oxygenation effects induced by NHF might not avoid
desaturation. Conversely, NIV effectiveness has been
proved for preoxygenation in patients with severe
AHRF.44 Moreover, the combination of NHF with NIV
seems to maintain higher SpO2 levels during induction
with no severe desaturation (SpO2 <80%) compared to
NIV alone, since NHF and apneic oxygenation can be
continued after NIV is removed.45 The ﬁnal word on
NHF vs NIV for preoxygenation in AHRF critically ill
patients might come from ongoing trials.46
Acute heart failure
Through the generation of low levels of PEEP and
improved oxygenation, HFNC resulted in positive hemo-
dynamic changes in New York Heart Association class III
patients as indicated by signiﬁcantly decreased inspiratory
collapse of the inferior vena cava and thus the preload of
the right ventricle.47 Consequently, NHF therapy seems
promising in acute cardiogenic pulmonary edema.
However, limited evidence exists on its application in
this context: Carratala Perales et al48 showed signiﬁcant
improvement of the intensity of dyspnea, respiratory rate
and oxygenation after 24 hours of HFNC treatment in 5
patients with acute heart failure and refractory hypoxemia
despite NIV. To date, no randomized clinical trial has been
published comparing NHF with NIVor standard oxygen in
acute heart failure or acute myocardial infarction patients.
Procedural sedation
Procedural sedation is widely used to achieve safe adequate
patient tolerance of several invasive procedures in the
respiratory medicine, interventional gastroenterology, and
cardiology ﬁelds. Due to the expected side effects of the
sedative drugs (eg, propofol, benzodiazepines, opioids), the
respiratory drive is depressed, reﬂexes are inhibited and
upper airways might be occluded. Hence, oxygen saturation
may fall despite oxygen supplementation.
NHF has been proposed as an ideal oxygenation device
since it allows oral passage of the operative tools while
improving oxygenation during the procedure through PEEP
effect and additional oxygen. Lucangelo et al prospectively
randomized 45 nonhypoxemic patients undergoing
bronchoscopy to NHF set at 40 L/minute with 50% FiO2,
NHF set at 60 L/minute with 50% FiO2, or Venturi mask
with 50% FiO2 during the procedure.
49 With similar seda-
tive drugs dosage and procedure duration among groups,
NHF set at 60 L/minute granted more adequate oxygenation
(higher SpO2 and PaO2/FiO2 compared to the other treat-
ments) at the end and shortly after the procedure, thus being
a reasonable option during routine bronchoscopy in patients
with mild respiratory dysfunction.
Simon et al50 compared the use of NHF at 50 L/min to
NIV in critically ill patients with moderate to severe
hypoxemia during bronchoscopy: patients treated with
NIV showed better oxygenation during and after the pro-
cedure, however patients treated by NHF maintained
acceptable peripheral oxygenation throughout the proce-
dure (minimum value 92±7%). In a similar cohort of
patients, La Combe et al51 tested the efﬁcacy of NHF
therapy at 50–60 L/min with only 5/30 patients requiring
escalation of therapy within 24 hrs after bronchoscopy.
These studies suggest the efﬁcacy and safety of NHF
during bronchoscopy also in patients with compromised
respiratory function.
NHF therapy seems promising as respiratory support also
in procedural sedation during dental surgery,52 and during
percutaneous balloon aortic valvuloplasty under continuous
monitoring with transesophageal echocardiography.53
Finally, in a retrospective analysis of 238 patients undergoing
endoscopic retrograde cholangiopancreatography,54 NHF use
during deep sedation might be useful to avoid general anesthe-
sia in those patients considered at high risk of perioperative
mortality.
Mauri et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Open Access Emergency Medicine 2019:11114
Clinical indications for COPD
patients
According to the World Health Organization, 65 mil-
lion people worldwide suffer from moderate to severe
COPD, which is supposed to become the third leading
cause of death by 2020.55,56 NIV is the ﬁrst-line
respiratory support for hypercapnic ARF. However, it
is applied intermittently, usually with periods of unsup-
ported spontaneous breathing with conventional O2
interspersed between NIV sessions. Standard O2 has
several drawbacks that may limit the beneﬁt of inter-
mittent NIV in hypercapnic ARF: limited gas ﬂow; cold
and dry gases leading to discomfort and under-humidi-
ﬁcation. In this scenario, the role of NHF could open
new perspectives in the management of both acute and
chronic hypercapnic COPD patients, when applied dur-
ing breaks from NIV, and a dedicated study might
unveil the advantages of NHF support soon.57
During COPD both lung compliance and airway
resistance increase and the physiologic breathing pat-
tern with lower respiratory rate and higher variability
could be beneﬁcial in COPD patients. In COPD
patients, the PEEP generated by NHF could stent the
early-collapsing bronchioles, counterbalancing—at
least in part—the intrinsic positive end-expiratory pres-
sure (PEEPi), and improving the alveolar gas exchange
(both hypoxia and hypercapnia). As the end-expiratory
airway pressure is increased by NHF, the work of
breathing needed to overcome both elastic and resistive
components is lower for the same tidal volume. Being
the initial airway pressure higher with the small PEEP
generated by NHF, the work of breathing, which should
overcome both elastic and resistive components of the
lung, is lower for the same tidal volume during NHF .
More than the PEEP effect, two major mechanisms of
NHF can provide a strong pathophysiological rationale
for its application in hypercapnic COPD patients: (1)
the reduction of work of breathing via the reduction of
inspiratory resistance: as the upper airway resistance
from nares to trachea constitutes about two thirds of
total airway resistance, NHF reaches past the nasal
valve leading to a signiﬁcant reduction of inspiratory
work of breathing. As is well documented in an elegant
study by Adams et al,58 during the inspiratory phase,
NHF rates elevate tracheal pressure, but the latter
reaches more rapidly the zero and negative pressure;
then, from this point and until the end of inspiration,
no muscular efforts are spent to overcome the upper
airway resistance; (2) the washout of upper airways
dead space. Recently, Biselli et al have reported that
in COPD patients during sleep, the degree of physio-
logical dead space at baseline correlates with its reduc-
tion during NHF.59 Interestingly, the reduction in
minute ventilation observed during NHF was due to a
reduction of Vt without changes in RR apart from one
case. It is important to underline that despite the
decrease of Vt, NHF was associated to a signiﬁcant
reduction in transcutaneous CO2, indicating higher efﬁ-
ciency of the minute ventilation.
Acute hypercapnic respiratory failure
Kim et al performed a single center retrospective study on
thirty-tree patients admitted to the medical intensive care
unit for ARF with hypercapnia (PaCO2 56.3±10.7 mmHg)
and treated with conventional oxygen therapy (COT) or
NIV.60 NHF was applied when the patients did not improve
or for intolerance to NIV. Once started, NHF decreased
PaCO2 after both 1 and 24 hours of treatment, resulting in
a signiﬁcant improvement of hypercapnia; furthermore,
NHF efﬁcacy was irrespective of whether chronic hyper-
capnia was present or not. However, a similar decrease in
PaCO2 was obtained with COT and NIV, too. It should be
noted that patients in this study might have already achieved
a clinical stability when started on NHF, as indicated by the
absence of respiratory acidosis despite hypercapnia (mean
PaCO2 mmHg, but mean normal pH was 7.37). Thus, we
cannot exclude that the initial treatment with NIVor simply
the medical therapy was the determinant of hypercapnia
correction, independently from the type of respiratory sup-
port. Furthermore, NHF was applied if no clinical improve-
ment with COT or NIV was observed, but “no clinical
improvement” does not necessarily mean “clinical failure”.
Finally, the etiology of respiratory failure was extremely
heterogeneous (pneumonia, acute exacerbation of COPD,
worsening of interstitial lung disease, cardiogenic edema,
extrapulmonary acute lung injury) and no clinical severity
score was reported. The study by Kim et alshowed feasi-
bility of NHF as an alternative to COT and NIV in stable
COPD patients.
In another prospective observational trial,61 Lee et
alcompared the effectiveness of NHF and NIV for the
treatment of severe acute exacerbation of COPD
(AECOPD) with moderate hypercapnia. The primary end-
point was the intubation rate and 30-day mortality. The
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patients were randomly assigned to receive either NIV or
NHF. The authors reported that PaO2, PaCO2 and pH
collected at 6 and 24 hours from the beginning of the
treatment were not signiﬁcantly different between groups.
No difference in intubation rate nor in 30-day mortality
was found. Notably, among the 88patients studied, the
etiology of AECOPD was unknown in 18; in the remain-
ing 70 patients, the etiology was pneumonia in 37 patients
and upper respiratory tract infection in the other 21
patients. Similarly to the study by Kim et al, grouping
under the deﬁnition of AECOPD different pathologies
makes it difﬁcult to interpret the net effect of NHF.
The clinical efﬁcacy and safety of NHF compared to
low-ﬂow oxygen via nasal cannulae or mask, continuous
positive airway pressure and bi-level positive airway pres-
sure, in adult COPD patients hospitalized in the ICU, were
analysed in the 2017 Cochrane systematic review. Pooled
data analysis revealed no differences in carbon dioxide
clearance between groups.62
Finally, in a large multicenter randomized trial on
adults presenting to the emergency department with
mixed hypoxemic or hypercapnic respiratory failure
requiring noninvasive ventilation,63 patients were ran-
domly assigned to receive NHF or NIV. The study evi-
denced similar improvement in the PaCO2 levels over time
in both arms, in the whole population and in the subgroup
with initial PaCO2 greater than 45 mmHg.
These studies indicate that NHF is feasible and safe in
the treatment of AECOPD patients and might be correlated
with improved physiology, like NIV but with a much easier
setup. Well conducted randomized trials in AECOPD com-
paring the clinical efﬁcacy of HFNC vs COT or NIV are
still lacking. The etiology of hypercapnia should become a
more central focus to move forward with future studies.
NHF in the emergency department
The use of NHF has been reported in the whole spectrum of
the critical care settings, including ICUs and perioperative
medicine, both for hypoxic and hypercapnic ARF. There
issome initial evidence on the use of NHF in patients
admitted to the emergency department (ED) with dyspnea,
too. A prospective, observational study was conducted in the
ED by Lenglet et al.64 Their study showed physiological
improvements of dyspneic patients by NHF, such as
decreased RR, and dyspnea scores and increased SpO2.
Bell et al65 enrolled 100 patients presenting at the ED with
shortness of breath in a randomized controlled trial compar-
ing NHF with conventional O2. They described that the use
of NHF was associated with greater reduction in RR (>20%
from baseline) and lower need for escalation of respiratory
support. These results suggest that use of NHF is feasible and
effective in the ED and could be considered ﬁrst-line support
in patients with acute shortness of breath. Makdee et al66 also
found that NHF may decrease the severity of dyspnea during
the ﬁrst hour of treatment in ARF due to congestive heart
failure in the ED, compared to COT.
Since these data are not sufﬁcient to deﬁne feasibility
and efﬁcacy of NHF in patients presenting with ARF at the
ED, a few concerns should be brought to the attention of
emergency physicians.67 When a patient is admitted to the
ED, the primary aim of the attending physician should be
to perform accurate diagnosis. Before starting NHF, sev-
eral aspects of the patient's condition should be evaluated,
including severity of illness and need for ICU admission.
Indeed, NHF can mask severe conditions, delaying diag-
nosis and escalation of treatment. Initial NHF settings
could be based on diagnosis, too, as more hypoxic patients
or those with acute cardiogenic pulmonary edema could
beneﬁt more from higher ﬂow rate, while a lower rate
could be selected in hypercapnic ones. During NHF sup-
port, it is important to frequently reevaluate respiratory
parameters, including RR, SpO2, dyspnea score and com-
fort to detect early NHF failure.68
Safety issues during NHF support
One of the main concern during NHF support is the risk of
delayed endotracheal intubation in hypoxemic patients. In
a retrospective observational study, Kang et al69 showed
how NHF might unduly delay initiation of mechanical
ventilation and worsen patient outcome. They reported
that patients intubated after 48 hours from HFNC initiation
had higher overall ICU mortality after propensity score
adjustment and matching vs patients intubated within 48
hours. However, the criteria for intubation were not pro-
spectively standardized and the patients with delayed intu-
bation might have simply been overlooked by the staff
physicians.70 Moreover, in the Kang et al study, median
duration of NHF support in the group intubated after more
than 48 hours was 126 hours in comparison with 10 hours
in the <48 hours group. This induced Ricard et al71 to ask
whether leaving patients in respiratory distress for more
than 5 days, with all the associated clinical implications,
could have had a major impact on ICU mortality. Still,
failure to improve within 48 hours should be seen as a sign
of more severe lung injury. To this end, Roca et al72,73
proposed a new index, the ROX index, calculated as
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(SpO2/FiO2)/RR, to identify at 12 hours the patients at
higher risk of NHF failure. A ROX index ≥4.88 points
can identify patients who will likely heal, while ROX
<3.85 is associated with high probability of ending up
intubated. Other signs of respiratory distress such as
respiratory rate, use of accessory respiratory muscles, pre-
sence of thoraco-abdominal asynchrony and discomfort
measured within the ﬁrst hour ofNHF initiation were asso-
ciated with high risk of failure.27,74 Together with the
abovementioned clinical parameters, the radiological ana-
lysis of chest X-ray has been considered to predict failure.
Koga et al75 described that the extent of pleural effusion at
NHF initiation was associated with failure. Lung imaging
(ie chest X-ray, lung ultrasound or EIT) could have an
important role in the early identiﬁcation of patients with
extensive opacities or effusions and eventually fail-
ing NHF.
Major safety issues associated with use of NHF in the
neonatal population, such as pneumothorax or burn
lesions, are not reported in adults. However, another draw-
back might be severe patient discomfort. In a recent post-
hoc analysis of the FLORALI trial, Frat et al74 reported
higher patient discomfort after 1 hour in patients failing
NHF support vs those who were not intubated.
Patient discomfort might be also linked to insufﬁcient
air humidiﬁcation/high temperature. Mauri et al76 reported
that, independently from the set ﬂow rate, lower tempera-
ture with full humidiﬁcation is associated with lower
discomfort.
In a study performed in the ED,64 both patients (100%)
and caregivers (82%) judged NHF to be more comfortable
compared to standard oxygenation therapy. In the same
study, noise level generated by NHF (55 dB) was compar-
able to standard oxygen face mask (50 dB) and not higher
than ambient noise (60–70 dB). Altogether, 76% of care-
givers preferred NHF, compared to COT.
Available data in recent literature indicates that, despite
the signiﬁcant advantages provided by NHF to the man-
agement of ARF patients, around 30% of them will fail
and require invasive ventilation. Hence, ED physicians
should keep in mind that patients presenting higher com-
plexity should be monitored closely, for example presence
of an additional extrapulmonary organ failure is an early
indicator of risk of failure.77 In another study, Messika et
al78 reported that in a cohort of ARF patients the
Simpliﬁed Acute Physiology Score II was higher in
patients failing NHF, mostly due to additional hemody-
namic and neurologic dysfunctions. Roca et al,36 in a
cohort of lung transplant recipients re-admitted to the
ICU and supported by NHF, found that patients with
bilateral inﬁltrates and those needing vasopressors during
their ICU stay were more likely to end up intubated.
Consistent with these results was the ﬁnding by Koga et
al75 of a higher sequential organ failure assessment score
in ARF patients failing NHF, with similar relevance for all
the components of the score.
Conclusion
NHF is a powerful noninvasive respiratory support that
can positively impact the physiology of acute and chronic
respiratory failure patients. However, studies showing
translational beneﬁts on hard clinical outcomes are still
to come in most patient populations. Careful monitoring is
crucial to maximize NHF beneﬁts while limiting the risk
of delayed intubation.
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